Alyeska Investment Group, L.P. Gemini Therapeutics, Inc. Transaction History

Alyeska Investment Group, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $124,906 - $209,048	52,262 Added 8.96%	635,692 $1.85 Million
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $838,708 - $1.61 Million	-254,154 Reduced 30.34%	583,430 $2.36 Million
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $1.88 Million - $4.17 Million	297,463 Added 55.07%	837,584 $5.42 Million
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $6.11 Million - $9.72 Million	540,121 New	540,121 $6.34 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.